Cord blood platelet gel alone or in combination with photobiomodulation therapy for the treatment of oral ulcerations in patients with epidermolysis bullosa: A pilot clinical comparative study

To the Editor Epidermolysis bullosa (EB) is a rare group of genetically heterogeneous diseases, characterized by deficiencies in the synthesis of proteins involved in the adhesion of the connective tissue to the epithelium; the oral cavity is frequently involved but although oral bullae, ulcers and erosions are common, there are few published data about possible treatment.1 Photobiomodulation therapy (PBMT), previously known as lowlevel laser therapy, is a photonic application increasing used in medical and dental applications. At the proper dosing, PBMT can be used to stimulate wound healing without adverse effects and reduce the use of drugs; it can obtain different intracellular biological reactions to stimulate regenerative abilities, without undesired adverse effects, reducing also the pharmacological support.2,3 Recently, we performed a pilot evaluation of the efficacy and safety of a platelet gel derived from cord blood (CBPG) with PBMT for the treatment of EB oral mucosal lesions, with some promising results.4 Aim of this study was that of appraise the CBPG efficacy, with or without the use of PBMT, in this type of disease.